** Shares of drug developer GeoVax Labs GOVX.O fall 16% to 89 cents in extended trading
** The U.S. Department of Health and Human Services has decided to terminate GeoVax's COVID-19 vaccine project contract — SEC filing
** The reason for the termination is stated as "convenience to the government"
** GeoVax received a stop-work notice from Advanced Technology International $(ATI)$ directing them to halt all activities related to the project
** The project was funded by the Biomedical Advanced Research and Development Authority (BARDA), a division of HHS
** The COVID-19 vaccine was in the mid-stage trial
** As of last close, stock fell 5.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.